DBV Technologies Overview

  • Founded

  • 2002

Founded
  • Status

  • Public

  • Employees

  • 87

Employees
  • Stock Symbol

  • DBV

Stock Symbol
  • Share Price

  • $3.26

  • (As of Monday Closing)

DBV Technologies General Information

Description

DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. Its method of delivering biologically active compounds to the immune system is through self-administered and non-invasive products. It also explores potential applications of its platform in vaccines and other immune diseases.

Contact Information

Website
www.dbv-technologies.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
PAR
Primary Office
  • 177-181 Avenue Pierre Brossolette
  • 92120 Montrouge
  • France
+33 01 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DBV Technologies Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.26 $3.51 $2.36 - $11.51 $330M 93.9M 155K -$1.35

DBV Technologies Financials Summary

In Thousands,
USD 		TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 344,808 105,359 63,680 941,131
Revenue 0 0 0 0
EBITDA (77,435) (90,238) (148,381) (167,722)
Net Income (77,452) (97,809) (159,555) (172,011)
Total Assets 284,978 146,723 272,246 271,725
Total Debt 5,300 18,693 33,131 48,045
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DBV Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DBV Technologies‘s full profile, request access.

Request a free trial

DBV Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The compan
Drug Discovery
Montrouge, France
87 As of 2022
00000
000000000 00000

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna al
0000000000000
San Francisco, CA
000 As of 0000
00.000
000000000 00.000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariat
000000000000000
Boulder, CO
000 As of 0000
00000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DBV Technologies Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nektar Therapeutics Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
000000 00000000 Formerly VC-backed Boulder, CO 000 00000 000000&0
000000 Formerly VC-backed Lyon, France 000 000.00 00000000 000.00
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 00000 000000&0 00000
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
You’re viewing 5 of 26 competitors. Get the full list »

DBV Technologies Patents

  • 132

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 14

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

DBV Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190231868-A1 Compositions of food allergens Active 04-Aug-2014 00000000
AU-2015299105-B2 Compositions of food allergens Active 04-Aug-2014 000000000
AU-2015299105-A1 Compositions of food allergens Active 04-Aug-2014 000000000
JP-6665159-B2 Food allergen composition Active 04-Aug-2014 000000000
JP-2017526663-A Food allergen composition Active 04-Aug-2014 A61K39/35
To view DBV Technologies’s complete patent history, request access »

DBV Technologies Executive Team (20)

Name Title Board Seat Contact Info
Daniel Tasse Chief Executive Officer & Board Member
Sebastien Robitaille Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Pascal Wotling Chief Technical Operations Officer & Chief Quality Officer
Pharis Mohideen MD Chief Medical Officer
Michele Robertson Chief Legal Officer
You’re viewing 5 of 20 executive team members. Get the full list »

DBV Technologies Board Members (15)

Name Representing Role Since
Adora Ndu DBV Technologies Board Member 000 0000
Daniel Soland Self Board Member 000 0000
Daniel Tasse DBV Technologies Chief Executive Officer & Board Member 000 0000
Julie O'Neill Self Board Member 000 0000
Mailys Ferrere Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

DBV Technologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DBV Technologies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DBV Technologies‘s full profile, request access.

Request a free trial